Bio Essence CORP 10-Q quarterly reports

Bio Essence Corp. reported a significant surge in revenue for the first quarter of 2026, driven by a substantial increase in OEM service orders.

Bio Essence Corp. reported significantly reduced net losses and a strategic pivot to OEM services, yet faces substantial doubt about its ability to continue as a going concern.

Bio Essence Corp. reports improved operational results in continuing segments but faces severe liquidity issues with zero cash and a going concern warning.

Bio Essence Corp. reports a net loss of $205,752 for Q1 2025 and acknowledges substantial doubt about its ability to continue as a going concern.

Bio Essence Corp. has filed an amendment to its Form 10-Q for the quarter ended June 30, 2024, to update disclosures regarding internal controls, while the rest of the report remains unchanged.

Bio Essence Corp. has filed an amended quarterly report to address internal control deficiencies and reflect the sale of two subsidiaries, impacting financial results for the period ending March 31, 2024.

Bio Essence Corp.'s Q3 2024 results show a net loss, the impact of discontinued operations, and ongoing concerns about the company's ability to continue as a going concern.

Bio Essence Corp.'s Q2 2024 results reveal a net loss despite increased revenues from continuing operations and gains from discontinued operations, raising concerns about the company's ability to continue as a going concern.

Bio Essence Corp. has filed an amended quarterly report on Form 10-Q/A for the period ended March 31, 2024, to update disclosures regarding internal controls and restate certain financial figures.

Bio Essence Corp. files an amended quarterly report (Form 10-Q/A) for the period ended March 31, 2024, reporting a net income of $133,939, primarily due to gains from the disposal of subsidiaries, while also restating prior period financials due to accounting errors.

Bio Essence Corp. files an amended quarterly report on Form 10-Q/A to include iXBRL data, with the rest of the report remaining unchanged.

Bio Essence Corp.'s Q2 2024 results reveal a net loss of $81,740, despite a gain from the disposal of discontinued operations, and the company expresses doubt about its ability to continue as a going concern.

Bio Essence Corp. announces a net income of $223,752 for the quarter ended March 31, 2024, primarily driven by gains from the disposal of discontinued operations, despite ongoing concerns about the company's ability to continue as a going concern.